EQS-News: MPH Health Care AG
/ Key word(s): Half Year Report/Half Year Results
MPH Health Care AG: Half-year result 2023
Preliminary IFRS result for the first half of 2023 published. Equity (net asset value) increases from 188.0 mn euros as of 31 March 2023 to 206.0 mn euros as of 30 June 2023. This corresponds to 48.12 euros per share (previous year 30 June 2022: 36.51 euros). The equity ratio is 93.3%. Berlin, 7 September 2023 - MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated result for the first half of 2023. Accordingly, equity decreased from 221.4 mn euros as of 31 December 2022 to 206.0 mn euros as of 30 June 2023. The net asset value (NAV) per share thus amounts to 48.12 euros. At the same time in the previous year, the NAV was 36.51 euros per share. The year-over-year increase is around 32%. The equity ratio as at 30.06.2023 remained high at 93.3% compared to 31.12.2022 (93.4%). The IFRS result for the first half of 2023 was -15.4 mn euros (previous year -36.0 mn euros). This result is mainly due to book losses in the context of the fair value measurement of the participations as at the reporting date, which do not affect liquidity. MPH AG is an investment company whose investments are reported as financial assets under the balance sheet item "Financial assets" and are valued "at fair value through profit or loss" on the balance sheet date. The net loss for the period results primarily from the fair value measurement of the listed investments held as at the balance sheet date, which is due to the lower stock market prices of the investments compared to the previous year's balance sheet date of 31 December 2022. The share price of the investment M1 Kliniken AG decreased from 9.06 euros on 31 December 2022 to 7.98 euros on 30 June 2023. On 6 September 2023 the share price was already back at 8.72 euros. The share price of the investment CR Energy AG decreased slightly from 32.00 euros on 31.12.2022 to 31.70 euros on 30.06.2023. "We are confident about the development in 2023 despite the ongoing situation in Ukraine and the increased energy costs. The approval of our own botulinum toxin in the private label segment continues to progress according to plan. CR Energy AG is very well positioned with its vertically integrated investment portfolio in the areas of "sustainable energy supply concepts" and "quality and cost-optimised housing". MPH can also benefit systematically from the positive developments of the investments in the coming years ", says Patrick Brenske, CEO of MPH. The half-year report of MPH Health Care AG was published on the website on 7 September 2023. About MPH Health Care AG: MPH AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. But MPH also exploits potential from high-growth and high-return sectors outside the healthcare market. Contact: Patrick Brenske, Management Board Corporate Communications E-Mail: ir@mph-ag.de
07.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | MPH Health Care AG |
Grünauer Straße 5 | |
12557 Berlin | |
Germany | |
Phone: | 030 / 863 21 45 60 |
Fax: | 030 / 863 21 45 69 |
E-mail: | info@mph-ag.de |
Internet: | www.mph-ag.de |
ISIN: | DE000A289V03, DE000A289VT5 |
WKN: | A289V0 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1721273 |
End of News | EQS News Service |
|
1721273 07.09.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.